Overview

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the relapse rate in the French patient population with chronic hepatitis C (CHC) previously treated with PegInterferon Alfa-2b (Peg-IFN alfa-2b) plus Ribavirin according to standard clinical practice. Treatment was to be completed prior to the enrollment in the current study. The study will also aim to identify factors that are predictive of relapse. Relapse rate is defined as the percentage of patients with negative viral load at end of treatment who again have positive viral load at 6 months after the end of treatment.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Interferon alpha-2
Interferon-alpha
Peginterferon alfa-2b
Ribavirin